The proliferative nodule is a lesion that develops within a congenital nevus. It is usually small (less than 5 mm), sometimes multiple, with a slow growth rate, and has a black or dark brown, smooth, shiny surface. It usually involutes spontaneously. We report a newborn infant who, at birth, had a giant congenital nevus with a nodular, ulcerative, hemorrhagic lesion within it. Physical and neurologic examinations were normal. Radiologic studies at birth and subsequently were normal. A fragment of the lesion was biopsied and histologic findings were compatible with a diagnosis of proliferative nodule in a giant congenital nevus. The rest of the nodule regressed spontaneously after 4 months.

Flagellate erythema, described by Moulin in 1970 as reminiscent of the lesions produced by flogging and by other authors as zebra-like lesions, was noted first in association with bleomycin treatment, but later occasionally reported in relationship with dermatomyositis, mostly from Japan. It is characterized by linear, erythematous, cutaneous streaks, pruriginous or painful, arising on an oedematous background and disappearing spontaneously over several weeks. So far, fewer than five cases have been reported in association with dermatomyositis, but we now present a further one.

6] Purtilo DT, Lindei syndrome (AIDS) J, Volsky DJ. Clin Lab Med Acquired 1986;6:3 immune -26. Letters deficiency [7] Rubio FA, Robayna C, Herranz P, et al. Leishmaniasis presenting as a psoriasiform eruption in AIDS. Br J Dematol 1997; 1363792-806, [El Hell E, Hodgson C. The uptake of 3H-thymidine by epidermal cells in normal and psoriatic subjects. Br J Dermatol 1966:78:262-268.

La enfermedad de Devic, también llamada neuromielitis óptica, es una entidad autoinmune desmielinizante del Sistema Nervioso Central, poco común que compromete los nervios ópticos y la médula espinal, ocasionando pérdida de la agudeza visual y afección motora. A continuación, se presenta el caso clínico de una mujer de 25 años, que presenta signos de mielopatía y amaurosis súbitas, cumpliendo criterios para neuromielitis óptica. Se inicia tratamiento con bolos de metilprednisolona sin mejoría, decidiéndose administrar Rituximab con respuesta favorable temprana. El Rituximab pertenece al grupo de anticuerpos monoclonales anti-CD20, una opción importante ante la falta de respuesta a la primera línea de tratamiento.